Bayesian network-based survival prediction model for patients having undergone post-transjugular intrahepatic portosystemic shunt for portal hypertension

doi:10.3748/wjg.v30.i13.1859

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 13

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5037)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-6) series, Tables (1-2) series.

Item

Count

PDF

212

HTML

2583

Figures (1-6)

494

Tables (1-2)

452

Sum=3741

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

150

Download

923

Sum=1073

Apr 7, 2024 (publication date) through Nov 11, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Apr 7, 2024; 30(13): 1859-1870
Published online Apr 7, 2024. doi: 10.3748/wjg.v30.i13.1859

Table 1 Baseline characteristics of the study cohort, n (%)

Variable		Variable
Sex		None	151 (38.4)
Male	278 (70.7)	Small	138 (35.1)
Female	115 (29.3)	Moderate to large	104 (26.5)
Age (yr)		Pre-HE
< 60	307 (78.1)	No	387 (98.5)
≥ 60	86 (21.9)	Yes	6 (1.5)
Etiology of cirrhosis		SBP
Hepatitis B virus	254 (64.6)	Yes	106 (27.0)
Hepatitis C virus	16 (4.1)	No	287 (73.0)
Alcoholic	35 (8.9)	Type of stent
Autoimmune	40 (10.2)	Composite stent¹	265 (67.2)
Others	48 (12.2)	Viatorr^® stent	128 (32.6)
Diabetes		Pre-PVP (mmH₂O)
Yes	67 (17.0)	> 33.9	305 (77.6)
No	326 (83.0)	≤ 33.9	88 (22.4)
Hypertension		Post-PVP (mmH₂O)
Yes	27 (6.9)	> 23.1	295 (75.1)
No	366 (93.1)	≤ 23.1	98 (24.9)
Indications for TIPS		K (mmol/L)
Variceal bleeding	357 (90.8)	< 3.5	95 (24.2)
Refractory ascites	36 (9.2)	3.5-5.5	295 (75.1)
Formation of PVT		> 5.3	3 (0.8)
Yes	94 (23.9)	Na (mmol/L)
No	299 (76.1)	< 137	124 (31.6)
Endoscopic treatment history		≥ 137	269 (68.4)
Yes	115 (29.3)	BUN (mmol/L)
No	278 (70.7)	< 3.1	28 (7.1)
Splenectomy history		≥ 3.1	365 (92.9)
Yes	15 (3.8)	SCr (μmol/L)
No	378 (96.2)	≤ 106	356 (90.6)
Ascites		> 106	37 (9.4)
ALB (g/L)		PT (s)
< 40	330 (84.0)	≤ 14.5	54 (13.7)
≥ 40	63 (16.0)	> 14.5	339 (86.3)
ALT (U/L)	352 (88.0)	FIB (g/L)
≤ 50	350 (89.1)	< 2	216 (55.0)
> 50	43 (10.9)	≥ 2	177 (45.0)
AST (U/L)		Hb (g/L)
≤ 40	279 (71.0)	< 130	328 (83.5)
> 40	114 (29.0)	≥ 130	65 (16.5)
ALP (U/L)		WBC (10⁹/L)
≤ 135	342 (87.0)	< 3.5	236 (60.1)
> 135	51 (13)	3.5-9.5	144 (36.6)
GGT (U/L)		> 9.5	13 (3.3)
≤ 60	295 (75.1)	PLT (10⁹/L)
> 60	98 (24.9)	< 125	322 (81.9)
TBIL (μmol/L)		≥ 125	71 (18.1)
≤ 28	301 (76.6)	Child-Pugh grade
> 28	92 (23.4)	A	169 (43.0)
PA (mg/L)		B	185 (47.1)
< 150	321 (81.7)	C	39 (9.9)
≥ 150	72 (18.3)	MELD score
INR		Low risk	354 (90.1)
≤ 1.3	190 (48.3)	Medium risk	31 (7.9)
> 1.3	203 (51.7)	High risk	8 (2.0)

¹Combined stent: Covered stent + bare stent.

TIPS: Transjugular intrahepatic portosystemic shunt; PVT: Portal vein thrombosis; pre-HE: Preoperative hepatic encephalopathy; SBP: Spontaneous bacterial peritonitis; pre-PVP: Preoperative portal vein pressures; post-PVP: Postoperative portal vein pressures; K: Potassium; Na: Sodium; SCr: Serum creatinine; BUN: Blood urea nitrogen; ALB: Albumin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; GGT: Gamma-glutamyl transferase; TBIL: Total bilirubin; PA: Prealbumin; INR: International normalized ratio; PT: Prothrombin time; FIB: Fibrinogen; Hb: Hemoglobin; WBC: White blood cell count; PLT: Platelets; MELD: Model for end-stage liver disease.

Full Size Table

Table 2 Univariate survival analysis of patients having undergone transjugular intrahepatic portosystemic shunt surgery for portal hypertension

Variable	HR	95%CI	P value	Variable	HR	95%CI	P value
Age (yr)				< 40	1.00
< 60	1.00			≥ 40	0.39	0.16-0.97	0.043
≥ 60	3.64	2.24-5.89	< 0.001	AST (U/L)
Etiology of cirrhosis				≤ 40	1.00
Hepatitis B virus	1.00			> 40	1.73	1.07-2.81	0.026
Hepatitis C virus	0.85	0.20-3.53	0.820	ALP (U/L)
Alcoholic	3.23	1.74-5.99	< 0.001	≤ 135	1.00
Autoimmune	1.51	0.67-3.41	0.317	> 135	2.60	1.5-4.51	< 0.001
Others	1.34	0.64-2.78	0.434	TBIL (µmol/L)
Hypertension				≤ 28	1.00
No	1.00			> 28	2.65	1.64-4.29	< 0.001
Yes	3.75	1.89-7.44	< 0.001	PA (mg/L)
Indications for TIPS				< 150	1.00
Variceal bleeding	1.00			≥ 150	0.38	0.16-0.88	0.024
Refractory ascites	2.23	1.14-4.36	0.020	WBC (10⁹/L)
Ascites				< 3.5	1.00
None	1.00			3.5-9.5	1.70	1.04-2.76	0.033
Small	0.61	0.31-1.22	0.164	> 9.5	1.49	0.46-4.88	0.507
Moderate to large	2.51	1.48-4.26	< 0.001	Child-Pugh grade
Post-TIPS PVP (mmH₂O)				A	1.00
≤ 23.1	1.00			B	2.09	1.16-3.76	0.014
> 23.1	2.85	1.30-6.23	0.009	C	5.12	2.53-10.37	< 0.001
Na (mmol/L)				MELD score
< 137	1.00			Low risk	1.00
≥ 137	0.54	0.33-0.89	0.016	Medium risk	2.33	1.18-4.58	0.014
ALB (g/L)				High risk	5.98	2.38-15.05	< 0.001

Post-PVP: Postoperative portal vein pressures; Na: Sodium; ALB: Albumin; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; TBIL: Total bilirubin; PA: Prealbumin; WBC: White blood cell count; MELD: Model for end-stage liver disease.

Full Size Table

Citation: Chen R, Luo L, Zhang YZ, Liu Z, Liu AL, Zhang YW. Bayesian network-based survival prediction model for patients having undergone post-transjugular intrahepatic portosystemic shunt for portal hypertension. World J Gastroenterol 2024; 30(13): 1859-1870
URL: https://www.wjgnet.com/1007-9327/full/v30/i13/1859.htm
DOI: https://dx.doi.org/10.3748/wjg.v30.i13.1859